Timothy Ray Brown, known as "the Berlin patient," has begun taking PrEP to make sure he doesn't have to deal with an HIV diagnosis -- again.
The FDA approved the fixed-dose combination of emtricitabine and tenofovir alafenamide for PrEP, but advocates hope to see more research on the HIV prevention drug's efficacy for receptive vaginal sex for cisgender women and transgender men.
But given cost concerns, advocates question whether the benefits are enough to warrant dumping F/TDF as the go-to PrEP option.
April 18, 2019: lamivudine/raltegravir for PrEP; feminizing hormone may impact PrEP efficacy; why TAF has a better renal profile than TDF; the role of internet dating in HIV incidence trends.
E/C/F/TAF viability for dialysis patients; TAF safety following renal damage; mental health needs for American Indians; parenting desires of people with HIV.
On April 29, 2016, Health Canada licensed the sale and use of a new fixed-dose combination of two anti-HIV drugs sold under the brand name Descovy.
Descovy (emtricitabine/tenofovir alafenamide) is the third approved HIV drug to include tenofovir alafenamide (TAF), which has been shown to have better bone and kidney safety than its predecessor tenofovir disoproxil fumarate (TDF, Viread).
The FDA has approved Descovy, Gilead Sciences' latest combination pill containing emtricitabine and an updated version of tenofovir.